Properties (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:AstraZeneca
|
| gptkbp:awards |
biotech innovation award
|
| gptkbp:businessModel |
research and development
biopharmaceuticals commercialization |
| gptkbp:CEO |
gptkb:Dr._David_A._Kessler
|
| gptkbp:clinicalTrials |
gptkb:IgG_antibodies
ongoing Phase 1 completed pending Phase 2 Phase 3 efficacy studies safety studies long-term studies immune modulation IgE antibodies |
| gptkbp:collaborations |
universities
hospitals academic institutions laboratories research institutions patient advocacy groups clinical research organizations healthcare_providers |
| gptkbp:focus |
immunology
|
| gptkbp:focus_area |
biomarkers
therapeutics diagnostics |
| gptkbp:founded |
2013
|
| gptkbp:founder |
gptkb:Dr._David_A._Kessler
|
| gptkbp:funding |
Series A
Series B Series C |
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Syntimmune
|
| gptkbp:investmentFocus |
Venture capital
|
| gptkbp:market |
gptkb:Asia
gptkb:North_America Europe |
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
pharmaceutical companies |
| gptkbp:patentCitation |
biotechnology innovations
|
| gptkbp:products |
SYN-004
SYN-005 |
| gptkbp:research_areas |
cancer
autoimmune diseases inflammatory diseases |
| gptkbp:research_focus |
immune system
disease mechanisms therapeutic targets |
| gptkbp:technology |
monoclonal antibodies
biologics |
| gptkbp:tributaryOf |
clinical candidates
preclinical candidates therapeutic candidates |
| gptkbp:website |
www.syntimmune.com
|